Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Revenue | 5.64 | 8.36 | 9.44 | 12.25 |
Total Revenue | 5.64 | 8.36 | 9.44 | 12.25 |
Costof Revenue Total | 2.66 | 3.36 | 5.61 | 8.74 |
Gross Profit | 2.98 | 5.00 | 3.83 | 3.51 |
Selling/ General/ Admin Expenses Total | 1.82 | 2.30 | 2.33 | 3.10 |
Research Development | 13.41 | 17.74 | 15.74 | 21.54 |
Depreciation/ Amortization | 0.57 | 0.63 | 0.66 | 0.67 |
Total Operating Expense | 6.39 | 8.07 | 10.17 | 14.66 |
Operating Income | -0.76 | 0.29 | -0.73 | -2.41 |
Interest Inc( Exp) Net- Non- Op Total | -3.70 | -15.00 | -14.82 | -16.34 |
Other Net | 0.03 | 0.01 | 0.03 | 0.05 |
Net Income Before Taxes | -1.10 | -1.19 | -2.18 | -3.99 |
Provisionfor Income Taxes | 0.09 | 0.56 | 1.08 | 0.97 |
Net Income After Taxes | -1.19 | -1.75 | -3.26 | -4.96 |
Net Income Before Extra Items | -1.19 | -1.75 | -3.26 | -4.96 |
Net Income | -1.19 | -1.75 | -3.26 | -4.96 |
Income Availableto Com Excl Extra Ord | -1.19 | -1.75 | -3.26 | -4.96 |
Income Availableto Com Incl Extra Ord | -1.19 | -1.75 | -3.26 | -4.96 |
Diluted Net Income | -1.19 | -1.75 | -3.26 | -4.96 |
Diluted Weighted Average Shares | 1.00 | 1.00 | 1.00 | 1.00 |
Diluted EPS Excluding Extra Ord Items | -1.19 | -1.75 | -3.26 | -4.96 |
Diluted Normalized EPS | -1.19 | -1.75 | -3.26 | -4.96 |
Other Operating Expenses Total | - | - | - | 0.00 |
Total Adjustmentsto Net Income | - | - | - | 0.00 |
Norris Medicines Dividend Norris Medicines Bonus Norris Medicines News Norris Medicines AGM Norris Medicines Rights Norris Medicines Splits Norris Medicines Board Meetings Norris Medicines Key Metrics Norris Medicines Shareholdings Norris Medicines Balance Sheet Norris Medicines Cashflow Norris Medicines Q1 Results Norris Medicines Q2 Results Norris Medicines Q3 Results Norris Medicines Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks